New Drugs - From Necessity to Delivery

Ewa Kedzierska; Lila Dabkowska; Tomasz Krzanowski; Ewa Gibula; Jolanta Orzelska-Gorka; Monika Wujec

doi:10.1515/cipms-2018-0020

.blurhash-client-img { display: none !important; }

New Drugs - From Necessity to Delivery

Current Issues in Pharmacy and Medical Sciences

Volume 31 (2018): Issue 2 (June 2018)

By: Ewa Kedzierska, Lila Dabkowska, Tomasz Krzanowski, Ewa Gibula, Jolanta Orzelska-Gorka and Monika Wujec

Open Access

|Jul 2018

Abstract

How to get a new drug to market? How much time does it take to go from the idea to implementation? In this study we followed the path drugs take from synthesis to introduction to the market. In doing so, articles in the PubMed and the Google Scholar database have been analyzed using the keywords: drug development, drug design, lead compound, preclinical trials, clinical trials. The available literature was subjectively selected due to its usefulness in the topic. Based on the obtained articles, we presented the stages that a would-be drug takes on the way from the idea to marketing. Herein, it is underlined that the process of creating new drugs is long, extremely labor-intensive, and involves many restrictions in the context of the use of animals, as well as humans

References

1. Schultes RE. The appeal of peyote (Lophophora williamsii) as a medicine. Am Anthropol. 1938;4:698-715.10.1525/aa.1938.40.4.02a00100
Open DOI Search in Google Scholar Back to article
2. Scarborough J. Drugs and medicines in the roman world. Expedition. 1996:38-51.
Search in Google Scholar Back to article
3. Patrick GL. An Introduction to Medicinal Chemistry. Wyd. 5. Oxford University Press; 2013.
Search in Google Scholar Back to article
4. Zając M, Pawełczyk E, Jelińska A. Chemia lekow dla studentow farmacji i farmaceutow. Wyd. 2. UM Poznań; 2006.
Search in Google Scholar Back to article
5. Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schaefer-Korting M. Farmakologia i toksykologia. Wyd. 3. Wrocław: Elsevier; 2012.
Search in Google Scholar Back to article
6. Silverman RB. Chemia organiczna w projektowaniu lekow. Warszawa: Wydawnictwo Naukowo-Techniczne; 2004.
Search in Google Scholar Back to article
7. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702.10.1038/nrd2030
Open DOI Search in Google Scholar Back to article
8. Matosiuk D, Fidecka S, Antkiewicz-Michaluk L, Dybala I, Koziol AE. Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine. Part 3. Synthesis and pharmacological activity of 1-aryl-5,6(1H)dioxo-2,3-dihydroimidazo [1,2-a]imidazoles. Eur J Med Chem. 2002;37:845-53.10.1016/S0223-5234(02)01407-1
Open DOI Search in Google Scholar Back to article
9. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science, 2008;322:881-8.10.1126/science.1156409
Open DOI Search in Google Scholar Back to article
10. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov. 2009;3:58-64.10.2174/187221309787158461
Open DOI Search in Google Scholar Back to article
11. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discoveryJ Med Chem. 2000;43:527-50.
Search in Google Scholar Back to article
12. Shi Y. Orphan nuclear receptors in drug discovery. Drug Discov Today. 2012;12:440-45.10.1016/j.drudis.2007.04.006
Open DOI Search in Google Scholar Back to article
13. Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J. 2006;8:E239-E253.10.1007/BF02854894
Open DOI Search in Google Scholar Back to article
14. Zucker KA, Adrian TE, Zdon MJ, Ballantyne GH, Modlin IM. Asperlicin: a unique nonpeptide cholecystokinin antagonist. Surgery. 1987;102:163-70.
Search in Google Scholar Back to article
15. Fitch RW, Spande TF, Garraffo HM, Yeh HJ, Daly JW. Phantasmidine: an epibatidine congener from the Ecuadorian poison frog Epipedobates anthonyi. J Nat Prod. 2010;73:331-7.10.1021/np900727e
Open DOI Search in Google Scholar Back to article
16. Kostis JB. Angiotensin converting enzyme inhibitors. I. Pharmacology. Am Heart J. 1988;116:1580-91.10.1016/0002-8703(88)90747-8
Open DOI Search in Google Scholar Back to article
17. Hollis A. Me-too drugs: is there a problem. WHO report. 2004.
Search in Google Scholar Back to article
18. Drews J. Drug discovery: a historical perspective. Science. 2000;287: 1960-64.10.1126/science.287.5460.196010720314
Open DOI Search in Google Scholar Open in PubMed Back to article
19. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, Leslie AG et al. The structural basis for agonist and partial agonist action on a β 1-adrenergic receptor. Nature. 2011;469:241.10.1038/nature09746302314321228877
Open DOI Search in Google Scholar Open in PubMed Back to article
20. Plunkett MJ, Ellman JA. Chemia kombinatoryczna i nowe leki. Świat Nauki. 1997;6:26-31.
Search in Google Scholar Back to article
21. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014;57:4977-5010.
Search in Google Scholar Back to article
22. Polak S, Wiśniowska B. Modelowanie komputerowe w badaniach nad lekiem - projektowanie i poszukiwanie cząstki aktywnej, ocena właściwości fizykochemicznych oraz aktywności biologicznej. Farm Pol. 2009;65:214-23.
Search in Google Scholar Back to article
23. Gruca A. Bioinformatyczne bazy danych. Warszawa: Wydawnictwo Polsko-Japońskiej Akademii Technik Komputerowych; 2010.
Search in Google Scholar Back to article
24. Berlicki L, Kafarski P. Computer-aided analysis and design of phosphonic and phosphinic enzyme inhibitors as potential drugs and agrochemicals. Curr Org Chem. 2005;9:1829-50.10.2174/138527205774913088
Open DOI Search in Google Scholar Back to article
25. Vogel G. Phylogenetic analysis: getting its day in court. Science. 1997;275:1559-60.10.1126/science.275.5306.15599072818
Open DOI Search in Google Scholar Open in PubMed Back to article
26. Honek, J. Preclinical research in drug development. Medical Writing. 2017;26:5-8.
Search in Google Scholar Back to article
27. Seńczuk W. Toksykologia wspołczesna. Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 2012.
Search in Google Scholar Back to article
28. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. London: Methuen & Co. Special edition published by Universities Federation for Animal Welfare (UFAW);1992.
Search in Google Scholar Back to article
29. Schollenberger A. Zasada 3R w ochronie zwierząt wykorzystywanych do badań naukowych. Życie Weterynaryjne. 2017;92.
Search in Google Scholar Back to article
30. Rusche B. The 3Rs and animal welfare-conf lict or the way forward. Altex. 2003;20:63-76.
Search in Google Scholar Back to article
31. Dodd A, Curtis PM, Williams LC, Love DR. Zebrafish: bridging the gap between development and disease. Hum Mol Genet. 2000;9:2443-9.10.1093/hmg/9.16.244311005800
Open DOI Search in Google Scholar Open in PubMed Back to article
32. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov. 2005;4:35-44.10.1038/nrd160615688071
Open DOI Search in Google Scholar Open in PubMed Back to article
33. Lieschke G, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet. 2007;8:353-67.10.1038/nrg209117440532
Open DOI Search in Google Scholar Open in PubMed Back to article
34. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496:498-503.10.1038/nature12111370392723594743
Open DOI Search in Google Scholar Open in PubMed Back to article
35. Pandey BU, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev. 2011;63:411-36.10.1124/pr.110.003293308245121415126
Open DOI Search in Google Scholar Open in PubMed Back to article
36. Brodniewicz T. Badania kliniczne. Wyd 1. Warszawa. CeDeWu. 2015.
Search in Google Scholar Back to article
37. Jachowicz R. Farmacja praktyczna. Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 2007.
Search in Google Scholar Back to article
38. Mahan V. Clinical trial phases. Int J Clin Med. 2014;5:1374-83.10.4236/ijcm.2014.521175
Open DOI Search in Google Scholar Back to article
39. National Centre for the Replacement, Refinement and Reduction of Animals in Research. https://www.nc3rs.org.uk/the-3rs (stan z 01.03.2018).
Search in Google Scholar Back to article
40. Portal Farmaceutyczno-Medyczny. Patent na lek. https://www.pfm.pl/artykuly/patent-na-lek/275 (stan z 01.03.2018).
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.1515/cipms-2018-0020 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 69 - 75

Submitted on: Mar 24, 2018

Accepted on: Apr 29, 2018

Published online: Jul 28, 2018

Published in print: Jun 1, 2018

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Keywords:

Related subjects:

Pharmacology, toxicology

© 2018 Ewa Kedzierska, Lila Dabkowska, Tomasz Krzanowski, Ewa Gibula, Jolanta Orzelska-Gorka, Monika Wujec, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 31 (2018): Issue 2 (June 2018)